Specialty pharmaceutical company developing Erwinaze for the treatment of pediatric acute lymphocytic leukemia
EUSA was created in 2006 to build a trans-Atlantic speciality pharma company. EUSA acquired several clinical assets and successfully guided Erwinaze, a first-in-class product for the treatment of certain cancers in children, to approval in the US.
Advent invested in the Series B financing in 2007. EUSA was acquired by Jazz Pharma in 2012 for $700m.